Discovery through Partnership | Excellence through Quality
| Product Name | Gemcitabine HCl |
| Description |
DNA polymerase inhibitor |
| Purity | >98% (HPLC); NMR (conforms) |
| CAS No. | 122111-03-9 |
| Molecular Formula | C9H11F2N3O4 • HCl |
| Molecular Weight | 299.7 |
| Field of Use | Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only. |
Properties
| Storage Temperature | -20ºC |
| Shipping Temperature | Shipped Ambient |
| Product Type | Inhibitor |
| Solubility | May be dissolved in DMSO (20 mg/ml); or Water (25 mg/ml) |
| Source | Synthetic |
| Appearance | Off-white powder |
| SMILES | C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F.Cl |
| InChI | InChI=1S/C9H11F2N3O4.ClH/c10-9(11)6(16)4(3-15)18-7(9)14-2-1-5(12)13-8(14)17;/h1-2,4,6-7,15-16H,3H2,(H2,12,13,17);1H/t4-,6-,7-;/m1./s1 |
| InChIKey | OKKDEIYWILRZIA-OSZBKLCCSA-N |
| Safety Phrases | Classification: Danger. Hazard Statements: H360. Precautionary Statements: P201 - P202 - P280 - P308 + P313 - P405 - P501 |
| Cite This Product | Gemcitabine HCl (StressMarq Biosciences Inc., Victoria BC CANADA, Catalog # SIH-623) |
Biological Description
| Alternative Names | 2′-Deoxy-2′,2′-difluorocytidine hydrochloride; dFdC |
| Research Areas | Cancer, Cell Signaling, DNA Synthesis, DNA/RNA, Epigenetics and Nuclear Signaling, Topoisomerases |
| PubChem ID | 60749 |
| Scientific Background | A clinically useful anticancer agent.1 It exerts its cytotoxic effects via the metabolites gemcitabine diphosphate (dFdCDP) and gemcitabine triphosphate (dFdCTP). dFdCTP is an inhibitor of DNA polymerase and is incorporated into DNA resulting in termination of chain elongation and apoptosis. dFdCDP is an inhibitor of ribonucleotide reductase which results in depletion of deoxyribonucleotides needed for DNA synthesis. The phosphates have also been reported to inhibit cytidine triphosphate synthetase (CTP synthetase)2 and deoxycytidylate deaminase (dCMP deaminase)3. Topoisomerase 1 has also been shown to be a target for gemcitabine.4 |
| References |
1. Mini E., et al. (2006) Ann. Oncol. 17 Suppl 5:v7. 2. Heinemann V., et al. (1995) Semin. Oncol. 22(4 Suppl 11):11. 3. Heinemann V., et al. (1992) Cancer Res. 52:533. 4. Pourquier P., et al. (2002) Clin. Cancer Res. 8:2499. |
Product Images
Powered by Bioz
Reviews
There are no reviews yet.